A Phase II Study of Single-Agent MLN9708 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) With Mutated Nucleophosmin-1 (NPM1+)
Phase of Trial: Phase II
Latest Information Update: 08 Apr 2019
Price : $35 *
At a glance
- Drugs Ixazomib (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 25 Jan 2016 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
- 13 Nov 2015 Status changed from suspended to recruiting as reported by ClinicalTrials.gov record.